YZi Labs’ investment will help Renewal Bio accelerate preclinical work on Stembroid™-derived stem cells for blood disorders and expand research in regenerative organ cell development.
According to YZi Labs’ official statement, its first biotechnology investment in Renewal Bio will fund preclinical studies of Stembroid™-derived hematopoietic stem cells targeting leukemia and immune diseases. The investment will also support Renewal Bio’s expansion into liver, heart, and pancreas cell research, enhancing the application of patient-specific regenerative medicine technologies.